跳到主要內容
Livermore
Livermore
中文EN

Thrive Capital Partners II, L.P. 的 Form 4 申報

Oscar Health, Inc.（OSCR），2026/9/18 申報

申報編號
0001193125-26-395847
申報時間
2026/9/18 20:21 ET
交易日
2026/9/18
申報延遲
當天
10b5-1 計畫
沒有勾選

這份申報列了 8 筆非衍生性交易、5 筆衍生性交易。交易當天就申報。

申報人

一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Thrive Capital Partners II, L.P.CIK 0001527725董事、持股 10% 以上大股東
Thrive Capital Partners III, L.P.CIK 0001556346董事、持股 10% 以上大股東
Claremount TW, L.P.CIK 0001575445董事、持股 10% 以上大股東
Thrive Capital Partners VII Growth, L.P.CIK 0001841736董事、持股 10% 以上大股東
Claremount VII Associates, L.P.CIK 0001841808董事、持股 10% 以上大股東
Thrive Partners III GP, LLCCIK 0001848080董事、持股 10% 以上大股東
Thrive Partners II GP, LLCCIK 0001848082董事、持股 10% 以上大股東
Thrive Partners VII GP, LLCCIK 0001877733董事、持股 10% 以上大股東
Thrive Partners VII Growth GP, LLCCIK 0001877735董事、持股 10% 以上大股東

非衍生性證券（表 I）

普通股等股票的取得與處分，每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2026/9/18Class A Common StockJ其他處分−6,268,097$0.00F1$00間接
2026/9/18Class A Common StockJ其他處分−75,520$0.00F1$00間接
2026/9/18Class A Common StockJ其他取得+1,323,589$0.00F1$01,323,589間接
2026/9/18Class A Common StockJ其他取得+4,855,810$0.00F1$04,855,810間接
2026/9/18Class A Common StockJ其他取得+164,218$0.00F1$0164,218間接
2026/9/18Class A Common StockJ其他處分−1,323,589$0.00F4$00間接
2026/9/18Class A Common StockJ其他處分−4,855,810$0.00F4$00間接
2026/9/18Class A Common StockJ其他處分−164,218$0.00F4$00間接

衍生性證券（表 II）

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2026/9/18Class A Common StockJ其他處分−1,323,589$0.00F1$04,779,730間接
2026/9/18Class A Common StockJ其他處分−4,855,810$0.00F1$017,535,258間接
2026/9/18Class A Common StockJ其他處分−164,218$0.00F1$0593,021間接
2026/9/18Class A Common StockJ其他取得+6,268,097$0.00F1$06,268,097間接
2026/9/18Class A Common StockJ其他取得+75,520$0.00F1$075,520間接

附註與備註

本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。

F1

On September 18, 2026, (i) Thrive Capital Partners II, L.P. ("Thrive II") transferred 1,307,831 and 15,758 shares of Class B Common Stock to Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and Claremount VII Associates, L.P. ("Claremount VII"), respectively, in exchange for 1,307,831 and 15,758 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively; (ii) Thrive Capital Partners III, L.P. ("Thrive III") transferred 4,798,003 and 57,807 shares of Class B Common Stock to Thrive VII Growth and Claremount VII, respectively, in exchange for 4,798,003 and 57,807 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively; (iii) Claremount TW, L.P. ("Claremount TW") transferred 162,263 and 1,955 shares of Class B Common Stock to Thrive VII Growth and Claremount VII, respectively, in exchange for 162,263 and 1,955 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively.

表 I 有 5 筆、表 II 有 5 筆交易的價格引用這則附註。

F4

On September 18, 2026, (i) Thrive II distributed to its limited partners and sole general partner, pro rata and without consideration, 1,323,589 shares of Class A Common Stock; (ii) Thrive III distributed to its limited partners and sole general partner, pro rata and without consideration, 4,855,810 shares of Class A Common Stock; and (iii) Claremount TW distributed to its limited partners and sole general partner, pro rata and without consideration, 164,218 shares of Class A Common Stock. Each of Thrive Partners II GP, LLC and Thrive Partners III GP, LLC, in turn, distributed to their members, pro rata and without consideration, the shares of Class A Common Stock received in the foregoing distributions. Such distributions were made in accordance with the exemptions afforded by Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

表 I 有 3 筆交易的價格引用這則附註。

備註

Joshua Kushner has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Kushner's representation, for purposes of Section 16 of the Exchange Act, each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Kushner has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.

看 SEC EDGAR 上的完整原文 （在新分頁開啟）